Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Identifieur interne : 001840 ( Main/Corpus ); précédent : 001839; suivant : 001841Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Auteurs : Marco Matucci-Cerinic ; Cosimo Bruni ; Yannick Allanore ; Massimo Clementi ; Lorenzo Dagna ; Nemanja S. Damjanov ; Amato De Paulis ; Christopher P. Denton ; Oliver Distler ; David Fox ; Daniel E. Furst ; Dinesh Khanna ; Thomas Krieg ; Masataka Kuwana ; Eun Bong Lee ; Mengtao Li ; Shiv Pillai ; Yukai Wang ; Xiaofeng Zeng ; Gloria TalianiSource :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2020.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (physiopathology), Humans (MeSH), Immunosuppressive Agents (administration & dosage), Immunosuppressive Agents (adverse effects), Lung Diseases, Interstitial (immunology), Lung Diseases, Interstitial (virology), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (physiopathology), Pneumonia, Viral (virology), Respiratory Distress Syndrome (drug therapy), Respiratory Distress Syndrome (virology), SARS-CoV-2 (MeSH), Scleroderma, Systemic (epidemiology), Scleroderma, Systemic (immunology), Scleroderma, Systemic (therapy), Scleroderma, Systemic (virology).
- MESH :
- chemical , administration & dosage : Immunosuppressive Agents.
- chemical , adverse effects : Immunosuppressive Agents.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- drug therapy : Coronavirus Infections, Pneumonia, Viral, Respiratory Distress Syndrome.
- epidemiology : Coronavirus Infections, Pneumonia, Viral, Scleroderma, Systemic.
- immunology : Lung Diseases, Interstitial, Scleroderma, Systemic.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- therapy : Scleroderma, Systemic.
- virology : Lung Diseases, Interstitial, Pneumonia, Viral, Respiratory Distress Syndrome, Scleroderma, Systemic.
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
DOI: 10.1136/annrheumdis-2020-217407
PubMed: 32349982
Links to Exploration step
pubmed:32349982Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.</title><author><name sortKey="Matucci Cerinic, Marco" sort="Matucci Cerinic, Marco" uniqKey="Matucci Cerinic M" first="Marco" last="Matucci-Cerinic">Marco Matucci-Cerinic</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy marco.matuccicerinic@unifi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Bruni, Cosimo" sort="Bruni, Cosimo" uniqKey="Bruni C" first="Cosimo" last="Bruni">Cosimo Bruni</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Allanore, Yannick" sort="Allanore, Yannick" uniqKey="Allanore Y" first="Yannick" last="Allanore">Yannick Allanore</name><affiliation><nlm:affiliation>Rheumatology Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name><affiliation><nlm:affiliation>Unit of Microbiology and Virology, San Raffaele Hospital, Milano, Lombardia, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Microbiology and Virology, Università Vita Salute San Raffaele, Milano, Lombardia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dagna, Lorenzo" sort="Dagna, Lorenzo" uniqKey="Dagna L" first="Lorenzo" last="Dagna">Lorenzo Dagna</name><affiliation><nlm:affiliation>Vita-Salute San Raffaele University, Milan, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Damjanov, Nemanja S" sort="Damjanov, Nemanja S" uniqKey="Damjanov N" first="Nemanja S" last="Damjanov">Nemanja S. Damjanov</name><affiliation><nlm:affiliation>Rheumatology department, University of Belgrade School of Medicine, Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="De Paulis, Amato" sort="De Paulis, Amato" uniqKey="De Paulis A" first="Amato" last="De Paulis">Amato De Paulis</name><affiliation><nlm:affiliation>Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Denton, Christopher P" sort="Denton, Christopher P" uniqKey="Denton C" first="Christopher P" last="Denton">Christopher P. Denton</name><affiliation><nlm:affiliation>Department of Rheumatology, Royal Free Hospital, University College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Distler, Oliver" sort="Distler, Oliver" uniqKey="Distler O" first="Oliver" last="Distler">Oliver Distler</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Fox, David" sort="Fox, David" uniqKey="Fox D" first="David" last="Fox">David Fox</name><affiliation><nlm:affiliation>Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E" last="Furst">Daniel E. Furst</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>University of Washington, Seattle, Washington DC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Khanna, Dinesh" sort="Khanna, Dinesh" uniqKey="Khanna D" first="Dinesh" last="Khanna">Dinesh Khanna</name><affiliation><nlm:affiliation>Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Krieg, Thomas" sort="Krieg, Thomas" uniqKey="Krieg T" first="Thomas" last="Krieg">Thomas Krieg</name><affiliation><nlm:affiliation>Translational Matrix Biology, Medical Faculty, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kuwana, Masataka" sort="Kuwana, Masataka" uniqKey="Kuwana M" first="Masataka" last="Kuwana">Masataka Kuwana</name><affiliation><nlm:affiliation>Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Eun Bong" sort="Lee, Eun Bong" uniqKey="Lee E" first="Eun Bong" last="Lee">Eun Bong Lee</name><affiliation><nlm:affiliation>Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Mengtao" sort="Li, Mengtao" uniqKey="Li M" first="Mengtao" last="Li">Mengtao Li</name><affiliation><nlm:affiliation>Rheumatology & Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Pillai, Shiv" sort="Pillai, Shiv" uniqKey="Pillai S" first="Shiv" last="Pillai">Shiv Pillai</name><affiliation><nlm:affiliation>Ragon Institute, Massachusetts General Hospital, Cambridge, Massachusetts, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yukai" sort="Wang, Yukai" uniqKey="Wang Y" first="Yukai" last="Wang">Yukai Wang</name><affiliation><nlm:affiliation>Rheumatology department, Shantou Central Hospital, Shantou, Guangdong, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zeng, Xiaofeng" sort="Zeng, Xiaofeng" uniqKey="Zeng X" first="Xiaofeng" last="Zeng">Xiaofeng Zeng</name><affiliation><nlm:affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Taliani, Gloria" sort="Taliani, Gloria" uniqKey="Taliani G" first="Gloria" last="Taliani">Gloria Taliani</name><affiliation><nlm:affiliation>Infectious Diseases Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Lazio, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32349982</idno><idno type="pmid">32349982</idno><idno type="doi">10.1136/annrheumdis-2020-217407</idno><idno type="wicri:Area/Main/Corpus">001840</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001840</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.</title><author><name sortKey="Matucci Cerinic, Marco" sort="Matucci Cerinic, Marco" uniqKey="Matucci Cerinic M" first="Marco" last="Matucci-Cerinic">Marco Matucci-Cerinic</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy marco.matuccicerinic@unifi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Bruni, Cosimo" sort="Bruni, Cosimo" uniqKey="Bruni C" first="Cosimo" last="Bruni">Cosimo Bruni</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Allanore, Yannick" sort="Allanore, Yannick" uniqKey="Allanore Y" first="Yannick" last="Allanore">Yannick Allanore</name><affiliation><nlm:affiliation>Rheumatology Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name><affiliation><nlm:affiliation>Unit of Microbiology and Virology, San Raffaele Hospital, Milano, Lombardia, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Microbiology and Virology, Università Vita Salute San Raffaele, Milano, Lombardia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dagna, Lorenzo" sort="Dagna, Lorenzo" uniqKey="Dagna L" first="Lorenzo" last="Dagna">Lorenzo Dagna</name><affiliation><nlm:affiliation>Vita-Salute San Raffaele University, Milan, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Damjanov, Nemanja S" sort="Damjanov, Nemanja S" uniqKey="Damjanov N" first="Nemanja S" last="Damjanov">Nemanja S. Damjanov</name><affiliation><nlm:affiliation>Rheumatology department, University of Belgrade School of Medicine, Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="De Paulis, Amato" sort="De Paulis, Amato" uniqKey="De Paulis A" first="Amato" last="De Paulis">Amato De Paulis</name><affiliation><nlm:affiliation>Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Denton, Christopher P" sort="Denton, Christopher P" uniqKey="Denton C" first="Christopher P" last="Denton">Christopher P. Denton</name><affiliation><nlm:affiliation>Department of Rheumatology, Royal Free Hospital, University College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Distler, Oliver" sort="Distler, Oliver" uniqKey="Distler O" first="Oliver" last="Distler">Oliver Distler</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Fox, David" sort="Fox, David" uniqKey="Fox D" first="David" last="Fox">David Fox</name><affiliation><nlm:affiliation>Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E" last="Furst">Daniel E. Furst</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>University of Washington, Seattle, Washington DC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Khanna, Dinesh" sort="Khanna, Dinesh" uniqKey="Khanna D" first="Dinesh" last="Khanna">Dinesh Khanna</name><affiliation><nlm:affiliation>Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Krieg, Thomas" sort="Krieg, Thomas" uniqKey="Krieg T" first="Thomas" last="Krieg">Thomas Krieg</name><affiliation><nlm:affiliation>Translational Matrix Biology, Medical Faculty, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kuwana, Masataka" sort="Kuwana, Masataka" uniqKey="Kuwana M" first="Masataka" last="Kuwana">Masataka Kuwana</name><affiliation><nlm:affiliation>Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Eun Bong" sort="Lee, Eun Bong" uniqKey="Lee E" first="Eun Bong" last="Lee">Eun Bong Lee</name><affiliation><nlm:affiliation>Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Mengtao" sort="Li, Mengtao" uniqKey="Li M" first="Mengtao" last="Li">Mengtao Li</name><affiliation><nlm:affiliation>Rheumatology & Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Pillai, Shiv" sort="Pillai, Shiv" uniqKey="Pillai S" first="Shiv" last="Pillai">Shiv Pillai</name><affiliation><nlm:affiliation>Ragon Institute, Massachusetts General Hospital, Cambridge, Massachusetts, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yukai" sort="Wang, Yukai" uniqKey="Wang Y" first="Yukai" last="Wang">Yukai Wang</name><affiliation><nlm:affiliation>Rheumatology department, Shantou Central Hospital, Shantou, Guangdong, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zeng, Xiaofeng" sort="Zeng, Xiaofeng" uniqKey="Zeng X" first="Xiaofeng" last="Zeng">Xiaofeng Zeng</name><affiliation><nlm:affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Taliani, Gloria" sort="Taliani, Gloria" uniqKey="Taliani G" first="Gloria" last="Taliani">Gloria Taliani</name><affiliation><nlm:affiliation>Infectious Diseases Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Lazio, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (physiopathology)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (administration & dosage)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Lung Diseases, Interstitial (immunology)</term><term>Lung Diseases, Interstitial (virology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (physiopathology)</term><term>Pneumonia, Viral (virology)</term><term>Respiratory Distress Syndrome (drug therapy)</term><term>Respiratory Distress Syndrome (virology)</term><term>SARS-CoV-2 (MeSH)</term><term>Scleroderma, Systemic (epidemiology)</term><term>Scleroderma, Systemic (immunology)</term><term>Scleroderma, Systemic (therapy)</term><term>Scleroderma, Systemic (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung Diseases, Interstitial</term><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung Diseases, Interstitial</term><term>Pneumonia, Viral</term><term>Respiratory Distress Syndrome</term><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32349982</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.</ArticleTitle><Pagination><MedlinePgn>724-726</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2020-217407</ELocationID><Abstract><AbstractText>Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Matucci-Cerinic</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy marco.matuccicerinic@unifi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bruni</LastName><ForeName>Cosimo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2813-2083</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allanore</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clementi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Microbiology and Virology, San Raffaele Hospital, Milano, Lombardia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Microbiology and Virology, Università Vita Salute San Raffaele, Milano, Lombardia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagna</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damjanov</LastName><ForeName>Nemanja S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Rheumatology department, University of Belgrade School of Medicine, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Paulis</LastName><ForeName>Amato</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denton</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0003-3975-8938</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Royal Free Hospital, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Distler</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-0546-8310</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furst</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington, Seattle, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>Dinesh</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1412-4453</Identifier><AffiliationInfo><Affiliation>Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krieg</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Translational Matrix Biology, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuwana</LastName><ForeName>Masataka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8352-6136</Identifier><AffiliationInfo><Affiliation>Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun Bong</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0003-0703-1208</Identifier><AffiliationInfo><Affiliation>Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4252-2889</Identifier><AffiliationInfo><Affiliation>Rheumatology & Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pillai</LastName><ForeName>Shiv</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ragon Institute, Massachusetts General Hospital, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yukai</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2468-3208</Identifier><AffiliationInfo><Affiliation>Rheumatology department, Shantou Central Hospital, Shantou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taliani</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Lazio, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="N">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">autoimmune diseases</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">scleroderma</Keyword><Keyword MajorTopicYN="Y">systemic</Keyword></KeywordList><CoiStatement>Competing interests: MMC reports grant and personal fees from Actelion, Biogen, Bayer, Boehringer Ingelheim, CSL Behring, Eli-Lilly, outside the submitted work. CB reports consultancy fee from Actelion, Eli Lilly. YA reports personal fees from Actelion, Bayer, BMS, Boehringer and Curzion, and grants and personal fees from Inventiva, Roche and Sanofi. MC; NSD: none. LD received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI. CPD has received consultancy fees and/or research grant funding from Actelion, GlaxoSmithKline, Bayer, Sanofi-Aventis, Inventiva, Boehringer Ingelheim, Roche, CSL Behring, UCB Pharma, Leadiant Biosciences, Corbus, Acceleron. OD had consultancy relationship and/or has received research funding from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd, CSL Behring, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Target Bio Science and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). Grants (2 Jahre) from Actelion, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma Patent issued: mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143). Comment: To investigate potential treatments of scleroderma and its complications. DF has received consulting fees, speaking fees and/or honoraria from Pfizer and research support from Regeneron, Gilead and Seattle Genetics. DEF: Grant/Research Support Corbus, Galapagos GSK, Pfizer, Talaris, CSL Behring, Mitsubishi; Consultant Actelion, Amgen, Corbus, Galapagos, Novartis, Pfizer, Roche/Genentech, Talaris, CSL Behring, Boehringer Ingelheim; DK reports personal fees from Actelion, Abbvie, Bayer, Boehringer-Ingelheim, Chemomab, Corbus, CSL Behring, Genentech/Roche, Gilead, GSK, Mitsubishi Tanabi, Sanofi-Aventis, UCB Pharma. He reports grants from Bayer, Boehringer-Ingelheim, Genentech/Roche, Pfizer, Sanofi-Aventis and has stock options in Eicos Sciences. MK has received consultancy fees and/or research grant funding from Abbvie, Actelion Pharmaceuticals, Astellas, Bayer, Boehringer Ingelheim, Chugai, Corbus, CSL Behring, Eisai, Mochida, Nippon Shinyaku, Novartis, Ono, Pfizer, Reata and Tanabe-Mitsubishi. SP reports SAB from Abpro. TK recieved consultancy fee and grant funding from Actelion.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32349982</ArticleId><ArticleId IdType="pii">annrheumdis-2020-217407</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-217407</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001840 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001840 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32349982
|texte= Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32349982" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |